MedTrace Logo

Effect of Different Concentrations of SPARC1102 on Allergic Conjunctivitis

NCT01320553 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 122

Last updated 2016-06-24

Study results available
· View outcomes & findings →

Summary

The present study will test if administration of different concentrations of 1334H eyedrops will be effective in treatment of allergic conjunctivitis in people with 10 yrs of age or older.

Conditions

  • Allergic Conjunctivitis

Interventions

DRUG

SPARC1102 I

SPARC1102 I will be administered in both eyes

DRUG

SPARC1102 II

SPARC1102 II will be administered in both eyes

DRUG

SPARC1102 III

SPARC1102 III will be administered in both eyes

DRUG

Vehicle

Vehicle will be administered in both eyes

Sponsors & Collaborators

  • Sun Pharma Advanced Research Company Limited

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
10 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2011-06-30
Primary Completion
2011-08-31
Completion
2011-09-30

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01320553 on ClinicalTrials.gov